Clinical Trials Logo

Lymphoproliferative Disorder clinical trials

View clinical trials related to Lymphoproliferative Disorder.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04883437 Recruiting - Clinical trials for Mantle Cell Lymphoma

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Start date: September 3, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.

NCT ID: NCT03258567 Recruiting - Lymphoma Clinical Trials

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Start date: April 26, 2018
Phase: Phase 2
Study type: Interventional

Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of some types of cancer or stops them from getting worse. To test the safety of the drug. Eligibility: People 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders or EBV-positive non-Hodgkin lymphomas with no standard therapy Design: Participants will be screened with: Medical history Physical exam Blood and urine tests CAT scan of the chest, abdomen, and pelvis Tumor and bone marrow biopsies (sample taken) Magnetic resonance imaging scan of the brain Lumbar puncture (also known as spinal tap) Positron emission tomography/computed tomography scan with a radioactive tracer Every 2 weeks, participants will get Nivolumab by vein over about 1 hour. They will also have: Physical exam Blood and pregnancy tests Review of side effects and medications During the study, participants will repeat most of the screening tests. They may also have other biopsies. After stopping treatment, participants will have a visit every 3 months for 1 year. Then they will have a visit every 6 months for years 2-5, and then once a year. They will have a physical exam and blood tests.

NCT ID: NCT02402244 Recruiting - Clinical trials for Malignant Solid Neoplasm

Project: Every Child for Younger Patients With Cancer

Start date: November 3, 2015
Phase:
Study type: Observational

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

NCT ID: NCT01137825 Recruiting - Lymphoma Clinical Trials

Registry of Older Patients With Cancer

Start date: September 2009
Phase:
Study type: Observational

RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

NCT ID: NCT01137643 Recruiting - Lymphoma Clinical Trials

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Start date: July 2009
Phase:
Study type: Observational

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.